Literatur
-
1 Bundesgeschäftsstelle für Qualitätssicherung .BQS Qualitätsreport 2005. 2006: 18-27
-
2
Mandell L A.
Epidemiology and etiology of community-acquired pneumonia.
Infect Dis Clin North Am.
2004;
18 (4)
761-76, vii
-
3
Dalhoff K, Marxsen J, Steinhoff J.
[Pneumonias and immunosuppression].
Internist (Berl).
2007;
48 (5)
507-508
-
4
Craven D E.
What is healthcare-associated pneumonia, and how should it be treated?.
Curr Opin Infect Dis.
2006;
19 (2)
153-160
-
5
Klevens R M, Morrison M A, Nadle J. et al .
Invasive methicillin-resistant Staphylococcus aureus infections in the United States.
JAMA.
2007;
298
1763-1771
-
6
Lonks J R, Garau J, Medeiros A A.
Implications of antimicrobial resistance in the empirical treatment of community-acquired respiratory tract infections: the case of macrolides.
J Antimicrob Chemother.
2002;
50 Suppl S2
87-92
-
7
Paterson D L.
“Collateral damage” from cephalosporin or quinolone antibiotic therapy.
Clin Infect Dis.
2004;
38 Suppl 4
S341-S345
-
8
Schrag S J, McGee L, Whitney C G. et al .
Emergence of Streptococcus pneumoniae with very-high-level resistance to penicillin.
Antimicrob Agents Chemother.
2004;
48 (8)
3016-3023
-
9
Yu V L, Baddour L M.
Infection by drug-resistant Streptococcus pneumoniae is not linked to increased mortality.
Clin Infect Dis.
2004;
39
1086-1087
-
10
Aspa J, Rajas O, Rodriguez D C. et al .
Impact of initial antibiotic choice on mortality from pneumococcal pneumonia.
Eur Respir J.
2006;
27
1010-1019
-
11
Song J H, Jung S I, Ki H K. et al .
Clinical outcomes of pneumococcal pneumonia caused by antibiotic-resistant strains in asian countries: a study by the Asian Network for Surveillance of Resistant Pathogens.
Clin Infect Dis.
2004;
38
1570-1578
-
12
Fuller J D, Low D E.
A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance.
Clin Infect Dis.
2005;
41
118-121
-
13
Bauer T T, Ewig S, Marre R. et al .
CRB-65 predicts death from community-acquired pneumonia.
J Intern Med.
2006;
260
93-101
-
14
Capelastegui A, Espana P P, Quintana J M. et al .
Validation of a predictive rule for the management of community-acquired pneumonia.
Eur Respir J.
2006;
27
151-157
-
15
Falagas M E, Siempos I I, Bliziotis I A. et al .
Impact of initial discordant treatment with beta-lactam antibiotics on clinical outcomes in adults with pneumococcal pneumonia: a systematic review.
Mayo Clin Proc.
2006;
81 (12)
1567-1574
-
16
Petitpretz P, Arvis P, Marel M. et al .
Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults.
Chest.
2001;
119
185-195
-
17
Hoffken G, Lorenz J, Kern W. et al .
[S3-guideline on ambulant acquired pneumonia and deep airway infections].
Pneumologie.
2005;
59
612-664
-
18
Vanderkooi O G, Low D E, Green K. et al .
A. Predicting antimicrobial resistance in invasive pneumococcal infections.
Clin Infect Dis.
2005;
40
1288-1297
-
19
Baddour L M, Yu V L, Klugman K P. et al .
Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia.
Am J Respir Crit Care Med.
2004;
170
440-444
-
20
Paul M, Nielsen A D, Gafter-Gvili A. et al .
The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis.
Eur Respir J.
2007;
30
525-531
-
21
Anderson K B, Tan J S, File T M. et al .
Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia.
Clin Infect Dis.
2003;
37
376-381
-
22
Davidson R, Cavalcanti R, Brunton J L. et al .
Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.
N Engl J Med.
2002;
346
747-750
-
23
Leroy O, Devos P, Guery B. et al .
Simplified prediction rule for prognosis of patients with severe community-acquired pneumonia in ICUs.
Chest.
1999;
116
157-165
-
24
Finch R, Schurmann D, Collins O. et al .
Randomized controlled trial of sequential intravenous (i. v.) and oral moxifloxacin compared with sequential i. v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment.
Antimicrob Agents Chemother.
2002;
46
1746-1754
-
25
Correa J C, Badaro R, Bumroongkit C. et al .
Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization.
Clin Ther.
2003;
25
1453-1468
-
26
Witte W, Strommenger B, Cuny C. et al .
Methicillin-resistant Staphylococcus aureus containing the Panton-Valentine leucocidin gene in Germany in 2005 and 2006.
J Antimicrob Chemother.
2007;
60
1258-1263
-
27
Witte W, Cuny C, Strommenger B. et al .
Emergence of a new community acquired MRSA strain in Germany.
Euro Surveill.
2004;
9
16-18
-
28
Fink M P, Snydman D R, Niederman M S. et al .
Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.
Antimicrob Agents Chemother.
1994;
38
547-557
-
29
Chastre J.
Antimicrobial treatment of hospital-acquired pneumonia.
Infect Dis Clin North Am.
2003;
17 (4)
727-737, vi
-
30
Yu V L, Chiou C C, Feldman C. et al .
An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome.
Clin Infect Dis.
2003;
37
230-237
-
31
Meehan T P, Chua-Reyes J M, Tate J. et al .
Process of care performance, patient characteristics, and outcomes in elderly patients hospitalized with community-acquired or nursing home-acquired pneumonia.
Chest.
2000;
117
1378-1385
-
32
Houck P M, MacLehose R F, Niederman M S. et al .
Empiric antibiotic therapy and mortality among medicare pneumonia inpatients in 10 western states: 1993, 1995, and 1997.
Chest.
2001;
119 (5)
1420-1426
-
33
Oosterheert J J, Bonten M J, Schneider M M. et al .
Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial.
BMJ.
2006;
333
1193
-
34
Dunbar L M, Wunderink R G, Habib M P. et al .
High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm.
Clin Infect Dis.
2003;
37
752-760
-
35
el Moussaoui R, de Borgie C A, van den Broek B P. et al .
Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study.
BMJ.
2006;
332
1355
-
36
Fein A M, Feinsilver S H, Niederman M S. et al .
“When the pneumonia doesn't get better”.
Clin Chest Med.
1987;
8
529-541
-
37
Arancibia F, Ewig S, Martinez J A. et al .
Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications.
Am J Respir Crit Care Med.
2000;
162
154-160
PD Dr. med. Bernhard Schaaf
Medizinische Klinik III, Universitätsklinikum Schleswig-Holstein, Campus Lübeck
Ratzeburger Allee 160
23538 Lübeck
eMail: schaaf@uni-luebeck.de
